OECD Home › Science and technology › Publications & Documents › Reports
This July 2009 symposium brought together the different communities – scientific, engineering, policy, public and legal – involved in synthetic biology and explored the opportunities and challenges posed by this emerging field.
This joint project builds on work undertaken by two separate OECD WPMN activities, former Project one (Development of an OECD database on Human Health and Environmental Safety Research) and former Project two (EHS Research strategies on Manufactured Nanomaterials).
This document is the report of the workshop held on 16-18 September 2009 in Washington D.C., United States, co-hosted by Business and Industry Advisory Committee (BIAC) and Society for Risk Analysis (SRA).
This is intended to provide delegations and other stakeholders with a “snapshot” of information on activities related to manufactured nanomaterials, as well as other activities on nanotechnologies, at the national and international level.
This book provides benchmarking tools on sustainable manufacturing and aims to spur eco-innovation through better understanding of innovation mechanisms.
The STI Scoreboard illustrates and analyses a wide set of indicators of science, technology, globalisation and industrial performance in OECD and major non-OECD countries. It includes the latest figures for R&D, foreign direct investment, risk capital and technology-related trade.
This country note, extracted from the STI Scoreboard 2009, explores recent developments in matters relating to innovation, science, technology and globalisation in the United States.
This book throws a spotlight on innovation across the software universe, setting out key issues and highlighting policy perspectives. It spans research and development, invention, production, distribution and use of software in the market.
This book presents the main results of the first large-scale effort to exploit firm-level data from innovation surveys across 20 countries in an internationally harmonised way, with a view to addressing common analytical questions.
This book reviews how the emergence of pharmacogenetics will impact the efficiency of pharmaceutical R&D and improve healthcare decision making and clinical care. It discusses what policies need to change in order for the public to reap the benefits from advances in diagnostic genetic testin